This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.
Our inaugural report is a groundbreaking exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery. Expert Insights We are honoured to have collaborated with renowned experts in the field of cell and gene therapy, who have generously shared their invaluable insights.
He then maintains that patients can access new therapies more quickly when the manufacturer relies on a brand-agnostic hub connected to a large network of providers and integrated with the systems those providers use daily. Shabbir explains the barriers that providers face when dealing with branded portals for multiple products.
Accelerate your cell therapy to clinic with a flexible CGMP-ready process The cell therapy market holds great promise, yet faces challenges like material variability and the need for standardization. Download this whitepaper to discover how to de-risk these challenges and meet the evolving needs of the cell therapy market.
Product Name: Audio Crystal Therapy One Time Offer. Click here to get Audio Crystal Therapy One Time Offer at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Therapy Series ! Crystal Healing Music.
Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Download CareMetx’s 2022 Report: The Evolving Landscape of Digital Healthcare Hubs to learn more about digital hub services and CareMetx’s solutions that improve the patient journey.
Logistics For Cell & Gene Therapy Trials: Specific Needs Demand Special Skills Download now to learn more about intricate trial logistics, the importance of expertise, navigating regulations, secure data management, and real case studies like viral vector therapy for Spinal Muscular Atrophy. A specialized provider is essential.
He describes patient-centric, data-driven solutions to help patients access, afford, and adhere to their therapies. To learn more, download CoverMyMeds’ 2022 Medication Access Report. John discusses some of the findings in CoverMyMeds’ recently published report on medication access. Read on for John’s insights.
Nasir discusses how hubs help patients initiate and adhere to drug therapies. Learn more by downloading CareMetx’s full report: The Evolving Landscape of Digital Healthcare Hubs. Today’s guest post comes from Nasir Ali, Chief Product Officer at CareMetx. Read on for Nasir’s insights.
Adam discusses how patients seeking to access specialty therapies can benefit from a digital intake approach. To learn about AssistRx’s digital intake solutions, download Digital Intake for Specialty Drug Programs: Q1 2024 Progress Report.
Today’s guest post comes from Rebecca Cotton, Executive Director of Strategy & Product Innovation at Cardinal Health ™ Sonexus ™ Access and Patient Support Rebecca discusses the essential features biopharmaceutical manufacturers should seek in a digital hub that will help patients get their therapies faster.
She highlights how GoodRx’s integrated pharma copay cards help to improve medication access, therapy adherence, and overall health outcomes. Click here to download the full report and learn more about partnering with GoodRx to drive patient access for your brand. Read on for Divya’s insights.
Plasmid DNA Design Considerations for Cell and Gene Therapy Cell and Gene therapy organizations must balance the need for rapid clinical progression and stringent quality expectations throughout development.
Stacey discusses digital hubs and the affordability advantages they offer both patients on specialty therapies and their health care providers. Download AssistRx's free 61-page eBook here: Specialty Drug Patient Support Programs: 2022 Progress Report.
Divya discusses the challenges patients face in accessing specialty therapies prescribed by their healthcare providers. Learn more about GoodRx’s insights and solutions for specialty treatments by downloading their free yellow paper: Access and Affordability Insights: Differences Across Specialties.
Product Name: The Neuro-Balance Therapy. Click here to get The Neuro-Balance Therapy at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Plus instantly download the digital version and bonuses absolutely free.
How cell and gene therapies are forcing sponsors to rethink safety and efficacy monitoring In this whitepaper, we look at how the industry is rising to the challenge, focusing on how cell and gene therapies are radically improving health outcomes and the technologies and techniques that are facilitating their development. Download Now.
Top 5 Reasons for Futureproofing Cell Therapy Development Starting with high quality reagents is one good way to futureproof cell therapy programs. Download this whitepaper examine when and how to transition to GMP critical reagents.
Accelerating the Development of Nucleic Acid Therapies at Harwell Science and Innovation Campus Harwell Campus offers rich opportunities for pioneering NAT technology on all fronts, and the campus is attracting biotechnology companies of all sizes – from Moderna to start-ups to Government research institutes and accelerators. Download here!
Gene therapy manufacturing: Custom and GMP-grade reagents to accelerate your scale-up plan Download now to learn how gene therapy manufacturers can overcome the unique challenges of scaling production.
You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy. We provide insights into how you can improve efficiency, success rates, and ultimately bring more effective therapies to market.
15, 2020 /PRNewswire/ — Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing.
View original content to download multimedia: [link].
Internal costs: The complexity of protocol designs a necessity for innovative therapies often requires more diverse patient populations, more extensive data collection and sophisticated trial methodologies, all of which demand higher financial outlays. Nearly 39% of sponsors cite these costs as primarily driven by complex protocols.
Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.
These internal issues are compounded by external pressures like inflation, the development of innovative therapies that require complex protocols and the need to comply with shifting regulatory requirements. Download the full report The post Key Trends Drug Developers Need to Know to Succeed appeared first on PPD.
Setting the Standard in CGT With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download this free guide to learn how we are setting the standard in cell and gene therapy, together.
Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Epilepsy Clinical Trials Finding an effective epilepsy treatment can be arduous.
Quantify Cancer With Methylation-Based ctDNA Detection Download this resource to accelerate your oncology clinical trials, optimize patient enrollment, and monitor minimal residual disease and molecular response effectively.
Erica discusses four technology areas that the healthcare network can embrace to increase speed to therapy, affordability, and adherence. To learn more about CoverMyMeds’ technology solutions, download their new whitepaper: Helping Patients Access Specialty Therapies: Autoimmune Conditions. Free download ).
How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies Early involvement of Medical Affairs in advanced therapies is pivotal. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes. Download to learn how Medical Affairs redefines healthcare and improves patient outcomes.
WHAT YOU WILL LEARN As expensive specialty therapies come to dominate drug spending, pharmaceutical manufacturers are paying a growing share of patents’ out-of-pocket costs for these prescriptions. Or, download this spreadsheet and email your registrants’ information to Tamra Feldman ( admin@drugchannels.net ).
HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), for the treatment of adult patients with Myasthenia Gravis (MG). View original content to download multimedia: [link]. CAMBRIDGE, Mass.
17, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity available for Lilly ‘s potential COVID-19 therapies. View original content to download multimedia: [link]. SOURCE Eli Lilly and Company.
By harnessing the full range of innovative technologies and taking advantage of an FSP partners extensive skills and experience, sponsors are able to bring their therapies to market more quickly and within budget even in the face of complicated global regulations and widely fluctuating workloads.
Primary endpoints of this study include safety, tolerability, and tumor response of the ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy. Outside of Japan , Illuminox therapies have not yet been approved as safe or effective by any regulatory authority. SAN MATEO, Calif. , ” About Rakuten Medical, Inc.
How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.
Download Your Copy. We respect your privacy, by clicking “Download Your Copy” you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement.
Balance risk and innovation in regulation using new digital-therapy products.
Beyond cfDNA: Harnessing the Power of Exosomes to Improve Sensitivity for Cancer Mutation Detection Liquid biopsy markers are advantageous because they can be used to assess overall prognosis, response to therapy, and likelihood of relapse or progression. Download now.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content